Vimpat (Lacosamide) Patent Expiration, LOE Window & CMS Spending

Vimpat (Lacosamide) by Ucb: FDA Orange Book LOE 2026-04-28, 12 AB generics, $131.5M 2024 CMS Part D & Medicaid spend, and 20 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUcb
FDA Application & PathwayN022253 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-04-28
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$131.5M
2024 Medicare Part D Spend$64.6M
2024 Medicaid Spend$66.9M
Reported Wholesale Price Change (CA SB 17)20 WAC filings (max 18.8% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.